HBM Healthcare Investments Reports Strong Nine-Month Financial Performance

HBM Healthcare Investments has published its quarterly report for the nine-month period ending on December 31, 2025. The company recorded a quarterly profit of CHF 191 million, bringing the total profit for the period to CHF 286 million. Despite facing negative currency effects amounting to approximately CHF 180 million, both private and public portfolios experienced positive momentum.

The company's net asset value (NAV) per share saw an 18% increase, while the share price surged nearly 30%. Public company assets grew by CHF 233 million, with private company investments contributing CHF 84 million to the profits. Significant developments included the sale of a majority stake in Swixx BioPharma and the acquisition of Bluejay Therapeutics by Mirum Pharmaceuticals.

The biotech market environment has improved, with expectations for continued M&A activities and a potential return of IPOs benefitting HBM Healthcare's portfolio. The company remains optimistic about the value creation potential of its investments.